## Retagliptin

Cat. No.: HY-112668A CAS No.: 1174122-54-3 Molecular Formula:  $C_{19}H_{18}F_6N_4O_3$  Molecular Weight: 464.36

Target: Dipeptidyl Peptidase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

## **SOLVENT & SOLUBILITY**

In Vitro

DMSO: 100 mg/mL (215.35 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1535 mL	10.7675 mL	21.5350 mL
	5 mM	0.4307 mL	2.1535 mL	4.3070 mL
	10 mM	0.2154 mL	1.0768 mL	2.1535 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution
- 3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.38 mM); Clear solution

## **BIOLOGICAL ACTIVITY**

**Description**Retagliptin (SP2086) is a selective, competitive and orally active dipeptidyl peptidase-4 (DPP-4) inhibitor. Retagliptin can be used for type 2 diabetes mellitus (T2DM) research<sup>[1]</sup>.

Retagliptin is a class of compound used for research of type 2 diabetes. Retagliptin inhibits the degradation of GLP-1, thus amplifying the incretin effect  $^{[1]}$ .

 $\label{eq:mce} \mbox{MCE has not independently confirmed the accuracy of these methods. They are for reference only.}$ 

In Vitro

REFERENCES	
[1]. Avivit Cahn, et al. An update o	on DPP-4 inhibitors in the management of type 2 diabetes. Expert Opin Emerg Drugs. 2016 Dec;21(4):409-419.
	Caution: Product has not been fully validated for medical applications. For research use only.
	Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
	Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com